Harnessing γδ T cells for B7-H3-targeting CAR therapy to enhance anti-tumor therapy in glioblastoma - PubMed
2 hours ago
- #Glioblastoma
- #Immunotherapy
- #CAR-γδ T cells
- The study focuses on using γδ T cells engineered with B7-H3-targeting CAR to enhance anti-tumor therapy in glioblastoma.
- Ethics approval for human sample use was obtained from the Ethics Committee of Xuanwu Hospital, Capital Medical University, with informed consent.
- Animal experiments were approved by the Institutional Animal Care and Use Committee of Beijing Friendship Hospital, Capital Medical University.
- The authors declared no conflicts of interest and all approved the manuscript for publication.
- References include key studies on glioblastoma classification, molecular methods, immunopathology, and the tumor microenvironment.